

ASX ANNOUNCEMENT

12 October 2021

ASX's request for further information on the trades by the former CEO and the late lodgement of former CEO's Appendix 3Y

EZZ Life Science Holdings Limited (ASX: EZZ) (Company) refers to the Appendix 3Y, lodged with the ASX on 6 October 2021, which reported that the former CEO, Luis Fernando Rodriguez Bravo:

- (a) sold 20,000 shares at \$0.83 per share on 15 March 2021 (**Sale**); and
- (b) bought 3,600 shares at \$0.52 per share on 19 May 2021 (**Purchase**).

ASX has asked the Company to provide the following further information in relation to the Sale and Purchase transactions:

The Sale and Purchase transactions first came to the attention of the Company on Monday, 27 September 2021, when the Company Secretary was reviewing the disclosures in the Company's draft financial statements for FY21. The Company Secretary contacted the former CEO via email (after reviewing the draft remuneration report) to query why the former CEO's shareholdings were not in accordance with the Initial Director's Interest Notice lodged with ASX. The former CEO responded to the Company Secretary's query by email on 5 October 2021 advising of the Sale and Purchase transactions.

In accordance with the Company's Securities Trading Policy (adopted by the Board on 22 December 2020), the Trading Periods in which a senior executive of the Company can trade the Company's shares are as follows:

- "(a) the period between 24 hours and 30 days following the release to ASX of the Company's half yearly results;*
- (b) the period between 24 hours and 30 days following the release to ASX of the Company's annual results;*
- (c) the period between 24 hours and 30 days following an annual general meeting of the Company;*
- (d) the duration of the offer period for an offer of the Securities or other financial products made pursuant to a prospectus, product disclosure statement, cleansing notice or other form of disclosure document issued by the Company; and*
- (e) any other period determined by the Board."*

The Company released its half-year financial statements for the period ending 31 December 2020 to the ASX on 1 March 2021, so the Sale transaction on 15 March 2021 was within the Trading Period referred to in paragraph (a) above.

The Purchase transaction on 19 May 2021 was not within any of the above Trading Periods, so was a purchase transaction during a closed period.

Following a meeting of the Board on 7 October 2021, to discuss the sale and purchase transactions, the Company's Chair invited the CEO to resign, which he did on 8 October 2021: see the Company's ASX release of 8 October 2021.

ASX has also asked the Company to provide the details of the arrangements that the Company has in place with its directors to ensure that it is able to meet its disclosure obligations under Listing Rule 3.19A:

After the Company listed on ASX in March 2021, the Board was provided with in-person training by an industry expert engaged by the Company to provide direction on disclosure requirements for directors of listed companies.

At the start of each Board meeting, directors are requested to provide disclosure of any relevant interests.

At every Board meeting the directors are provided with a Company Secretary Report which details the disclosure requirements regarding director shareholdings/interests and includes a relevant extract from the Securities Trading Policy which clearly outlines the trading windows. The report also includes the Directors' Shareholding Register, which is based on the information provided by the directors and clearly outlines the shares held by each director.

At every Board meeting the directors are also provided with an annual reporting schedule and periodic disclosure requirements which outlines the requirement for an Appendix 3Y (Change of Director's interests) to be given to the ASX no more than five business days after a director's appointment or no more than five business days after a change occurs.

The company is of the view that its current arrangements in relation to its trading policy and/or its disclosure obligations under Listing Rule 3.19A are adequate.

For the reasons mentioned in the paragraphs above, the Company considers its arrangements to be adequate.

In addition, the Company's Securities Trading Policy requires that a senior executive of the Company, who believes that trading is permitted under the Policy and proposes to deal in the Company's shares, is required to first provide:

“(a) written notice of their intention to trade to the Relevant Officer (being the Chairperson of the Board or, in the case of an application from the Chairperson, the Chair of the Audit and Risk Committee) and the Company Secretary; and

(b) confirmation that they are not in possession of any inside information.”

After dealing, a senior executive must confirm in writing to the Company Secretary, within 3 days that the dealing in the shares has occurred, the number of the shares affected and the relevant parties to the dealing.

Also, under the Company's Securities Trading Policy each Director that trades must notify the Company Secretary of any sale or purchase of the Company's shares so that the Company can notify the ASX.

Unfortunately, the requirements of the Company's Securities Trading Policy were not followed by the former CEO in relation to the Sale and Purchase transactions.

Although the Company's arrangements are considered adequate, the Company will undertake further training and require confirmation from directors and other senior executives that they are aware of their obligations.

The Company confirms that it is complying with the Listing Rules and, in particular, Listing Rule 3.1.

Authorised for release by the Board of EZZ Life Science Holdings Limited.

-Ends-

For further information, please contact:

Investor Relations

www.ezzlife.com.au/investors

ir@ezzlife.com.au

About EZZ Life Science Holdings

EZZ Life Science (ASX: EZZ) is a consumer products company headquartered in Sydney, Australia. EZZ develops, produces, and distributes its own range of consumer health products under the EZZ brand to retailers and consumers through on-line and off-line channels. It is also an exclusive wholesale distributor of EAORON skin care products for pharmacies, supermarkets and retailers in Australia and New Zealand. See more at: <https://www.ezzlife.com.au>